Paul C. Miller v. RxMapper, LLC, James Miller, Chris Grilli, and David Upjohn

Summary

The United States District Court for the District of Delaware addresses Defendants’ Rule 12(b)(6) motion to dismiss claims arising from the alleged forced sale and undervaluation of Plaintiff’s equity units in RxMapper, LLC. The court allows the federal securities claims and tortious-interference claim to proceed, but dismisses the fraud, negligent-misrepresentation, and conversion claims as improperly duplicative of the breach-of-contract claim. The breach-of-contract claim was not challenged by the motion.

Holdings

1. At the pleading stage, Plaintiff plausibly alleged that his membership interests were investment contracts and therefore securities because he had limited management power in a manager-managed LLC and the allegations did not show that he meaningfully participated in management or exercised more than minimal control over the company's performance.
2. The court denied dismissal of the securities claims on the forced-sale argument because Defendants did not address in their reply the case law Plaintiff cited in support of the forced-seller doctrine.
3. The fraud and negligent-misrepresentation claims were dismissed because the alleged misrepresentations and misconduct concerned duties imposed by the operating agreement, were not separate and distinct from the alleged breach, and did not allege damages separate from the contract damages.
4. The tortious-interference claim against the Individual Defendants survived dismissal because employees and directors may interfere with their organization's contract when acting beyond the scope of their roles, and whether they acted within that scope was a fact question not suitable for resolution on a motion to dismiss.
5. The conversion claim was dismissed because Plaintiff identified no right to the units or their value independent of the rights granted by the operating agreement.

Questions Presented

1. Whether the complaint plausibly alleged that Plaintiff's RxMapper membership interests were securities under the federal securities laws.
2. Whether the federal securities claims should be dismissed because the alleged mandatory sale involved no investment decision.
3. Whether the Delaware fraud and negligent-misrepresentation claims were impermissibly bootstrapped from the alleged breach of the operating agreement.
4. Whether the individual defendants could be liable for tortious interference with the contract between Plaintiff and RxMapper when they allegedly acted beyond the scope of their authority for personal reasons.
5. Whether the conversion claim was duplicative of the breach-of-contract claim because Plaintiff identified no property right independent of the operating agreement.

Disposition

other